WuXi Manufacturing Facility Passes FDA Inspection

Author(s):

WuXi PharmaTech completed a general GMP and pre-approval inspection from FDA.

The CRO/CMO WuXi PharmaTech, reports that its that its small-molecule API and advanced intermediate manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) completed a general GMP and pre-approval inspection from FDA with no Form 483 issued.

Source: WuXi PharmaTech

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!